Fisher L Mark, Pan Xiao-Su
Molecular and Metabolic Signalling Centre, Division of Basic Medical Sciences, St George's, University of London, Cranmer Terrace, London, UK.
Methods Mol Med. 2008;142:11-23. doi: 10.1007/978-1-59745-246-5_2.
DNA gyrase and DNA topoisomerase (topo) IV are the bacterial targets of coumarin and quinolone antimicrobial agents. Widespread resistance to clinically important antibiotics such as beta-lactams and macrolides has stimulated the development of novel gyrase and topo IV inhibitors especially against Streptococcus pneumoniae and other Gram-positive pathogens. Here, we describe how gyrase and topo IV activities are measured and how inhibitors of these enzymes may be assayed, focusing as a paradigm on DNA supercoiling by S. pneumoniae gyrase, DNA decatenation by S. pneumoniae topo IV, and DNA cleavage by both enzymes. These approaches provide mechanistic insight on inhibitor action and allow identification of dual gyrase/topo IV targeting agents that can minimize the emergence of bacterial resistance.
DNA 回旋酶和 DNA 拓扑异构酶(topo)IV 是香豆素类和喹诺酮类抗菌药物的细菌作用靶点。对β-内酰胺类和大环内酯类等临床上重要抗生素的广泛耐药性促使人们开发新型的回旋酶和拓扑异构酶 IV 抑制剂,尤其是针对肺炎链球菌和其他革兰氏阳性病原体的抑制剂。在此,我们描述了如何测量回旋酶和拓扑异构酶 IV 的活性以及如何检测这些酶的抑制剂,以肺炎链球菌回旋酶的 DNA 超螺旋、肺炎链球菌拓扑异构酶 IV 的 DNA 解连环以及这两种酶的 DNA 切割作为范例进行重点阐述。这些方法为抑制剂的作用机制提供了深入了解,并有助于鉴定能够最大限度减少细菌耐药性产生的双靶点回旋酶/拓扑异构酶 IV 靶向药物。